Advocacy intelligence hub — real-time data for patient organizations
University of Wisconsin, Madison — PHASE1, PHASE2
Merck Sharp & Dohme LLC — PHASE1, PHASE2
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — PHASE2
Ohio State University Comprehensive Cancer Center
Replimune Inc.
Ohio State University Comprehensive Cancer Center — NA
TuHURA Biosciences, Inc. — PHASE1
TuHURA Biosciences, Inc. — PHASE2, PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
BAVENCIO
EMD Serono
Bavencio
(avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1))Orphan drugEMD Serono Research and Development Institute, Inc.
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tu...
Zynyz
(retifanlimab-dlwr)Orphan drugstandardIncyte Corporation
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytoki...
Jason J Luke
Alliance for Clinical Trials in Oncology
📍 Philadelphia, Pennsylvania
Amanda Olson
M.D. Anderson Cancer Center
Shailender Bhatia, MD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA
Andrew Brohl, MD, M.D
Moffitt Cancer Center
📍 TAMPA, FL
Sergey V. Orlov, Professor
EuroCityClinic LLC
Shailender Bhatia, MD, MD
Fred Hutch/University of Washington Cancer Consortium
📍 SEATTLE, WA